King-eagle Med Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
864
- Latest Deal Type
-
IPO
- Financing Rounds
-
9
King-eagle Med General Information
Description
Provider of one-stop solutions from drug discovery to registration designed for pharmaceutical manufacturing. The company also provides drug research, clinical analysis and testing and drug and material manufacturing, enabling clients with pharmaceutical manufacturing.
Contact Information
Website
www.jingyiyiyao.comCorporate Office
- Lugu Technology Industrial Park, Wukuang
- No. 28, Lutian Road, High-tech Zone
- Changsha, Hunan 410200
- China
Corporate Office
- Lugu Technology Industrial Park, Wukuang
- No. 28, Lutian Road, High-tech Zone
- Changsha, Hunan 410200
- China
King-eagle Med Timeline
King-eagle Med Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
King-eagle Med Patents
King-eagle Med Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026523332-A | Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, its pharmaceutical composition, method of preparation, and its use as an anti-influenza agent. | Pending | 18-May-2023 | ||
| EP-4696693-A1 | Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof | Pending | 18-May-2023 | ||
| US-20260308174-A1 | Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof | Pending | 18-May-2023 | ||
| WO-2024234474-A1 | Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof | Inactive | 18-May-2023 | ||
| WO-2023213211-A1 | 2,4-disubstituted-5-fluoropyrimidine derivative, method for preparing same, and use thereof | Inactive | 06-May-2022 | C07D403/04 |
King-eagle Med Signals
King-eagle Med Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
King-eagle Med FAQs
-
When was King-eagle Med founded?
King-eagle Med was founded in 2010.
-
Where is King-eagle Med headquartered?
King-eagle Med is headquartered in Changsha, China.
-
What is the size of King-eagle Med?
King-eagle Med has 864 total employees.
-
What industry is King-eagle Med in?
King-eagle Med’s primary industry is BPO/Outsource Services.
-
Is King-eagle Med a private or public company?
King-eagle Med is a Private company.
-
What is King-eagle Med’s current revenue?
The current revenue for King-eagle Med is .
-
How much funding has King-eagle Med raised over time?
King-eagle Med has raised $41.2M.
-
Who are King-eagle Med’s investors?
Hunan Heng Chang Pharmaceutical Group, Xiangtan Industrial Investment, Hangzhou Hongcheng Capital, Hunan Djwk Medical, and Hunan Lugu Development Group are 5 of 9 investors who have invested in King-eagle Med.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process